Błąd cURL: Failed connect to www.viamedica.pl:443; No route to host
Vol 51, No 3 (2020)
Published online: 2020-09-01

open access

Page views 248
Article views/downloads 318
Get Citation

Connect on Social Media

Connect on Social Media

Chimeric antigen receptor T in the treatment of multiple myeloma – state of the art and future directions

Dominik Dytfeld1
DOI: 10.2478/ahp-2020-0023
Acta Haematol Pol 2020;51(3):120-124.


In spite of the introduction of several new drugs in the last 10 years, multiple myeloma (MM) remains incurable. Thus, an adoptive cellular therapy using chimeric antigen receptor T (CART), a strategy to increase the frequency of tumor-directed and functionally active T cells targeting antigens present on the cancer cell, might change the treatment in MM as it did in lymphoma and ALL. There are several targets for CART therapy in MM on different levels of development, which are discussed in the manuscript. B-cell maturation antigen (BCMA) being tested in the studies of phase 1–2 is the most promising, but so far CART has not been approved in the cure of MM and remains an experimental approach. The hematological society is facing a new technology which with its potential ability to cure MM, in spite of its complexity, cost, and toxicity, will definitely and soon change the landscape of myeloma in Europe and world-wide.

Article available in PDF format

View PDF Download PDF file
Błąd cURL: Failed connect to www.viamedica.pl:443; No route to host